UBS AM’s Tonix Pharmaceuticals TNXP Stock Holding History

UBS AM’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.8K	Hold	141	–	–	﹤0.01%	3557
2026 Q1	$1.94K	Buy	+141	New	+$2.17K	﹤0.01%	3602

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

UBS AM's TNXP Position: Q2 2026 in Review

UBS AM held its Tonix Pharmaceuticals (TNXP) position steady in Q2 2026 at 141 shares worth $1.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3557.

UBS AM first reported a position in TNXP in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.94K in Q1 2026. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

UBS AM held 141 shares of Tonix Pharmaceuticals worth $1.8K as of Q2 2026.
UBS AM left its Tonix Pharmaceuticals share count unchanged in Q2 2026.
Tonix Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3557 holding.
UBS AM first reported a position in Tonix Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
UBS AM's Tonix Pharmaceuticals position peaked at $1.94K in Q1 2026.
103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.